Is Mounjaro Tirzepatide? The Brand Name and the Drug Explained

Why the search for 'manjaro tirzepatide' lands on the same medicine

Tirzepatide is the generic, or international non-proprietary, name given to this molecule by the World Health Organisation's naming committee. Eli Lilly then chose Mounjaro as the brand name for the UK market, in the same way a drug manufacturer might name a product for recognition rather than chemistry. Search engines surface both terms because prescribers, pharmacists, clinical literature and patients all use them, sometimes in the same sentence. The full tirzepatide overview explains the science in more detail, but the short answer is simple: they are interchangeable labels for one drug, as our page on whether tirzepatide is the same as Manjaro also sets out clearly.

What does differ between sources is the dosing information you encounter. The UK-licensed Mounjaro KwikPen comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Treatment opens at 2.5 mg, a dose set by the SmPC to help the body adjust rather than to deliver the full therapeutic effect. From there, a prescriber titrates according to tolerance and response, typically in four-week steps. If you are still working out whether tirzepatide is in fact Mounjaro, that page addresses the question directly before you read further. For detail on how those steps work in practice, the Mounjaro treatment guide is worth reading alongside the official patient information leaflet.

One practical note on storage that often comes up: Mounjaro pens are kept refrigerated at 2–8°C. Many people simply slot the current pen into the fridge door, which is convenient, but the exact room-temperature window allowed if you're travelling is set out in the SmPC rather than here, because the answer matters clinically and should come from the official source.

The clinical evidence NICE and the MHRA relied on

When regulators licence a medicine, the evidence base is the foundation. For tirzepatide, the key dataset was the SURMOUNT programme. SURMOUNT-1, which randomised 2,539 adults with obesity and no diabetes, ran for 72 weeks and reported average weight reductions of around 20–21% at the 15 mg dose, published in the New England Journal of Medicine. That figure sits behind NICE's decision to recommend tirzepatide in technology appraisal TA1026, published in December 2024.

The head-to-head picture is also clinically settled. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4 mg over 72 weeks in 751 adults with obesity and no diabetes. Tirzepatide produced greater average weight loss in that open-label comparison. NICE's committee noted in its TA1026 discussions that indirect comparisons also favour tirzepatide, though individual responses vary. For anyone weighing tirzepatide against semaglutide, the Mounjaro or tirzepatide comparison page pulls that evidence together clearly.

Because tirzepatide carries a Black Triangle (▼) designation, the MHRA continues to collect real-world data beyond the trials. That monitoring sits alongside the yellow card scheme, where patients can report any suspected side effects at yellowcard.mhra.gov.uk. It is not a signal that the medicine is unsafe; it means regulatory scrutiny remains active, which is standard for newer medicines.

Who tirzepatide is licensed for in the UK, and what the consultation establishes

The UK licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, dyslipidaemia, type 2 diabetes, prediabetes or obstructive sleep apnoea. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. A BMI figure alone does not determine eligibility: the prescriber assesses the whole clinical picture, including other medicines, medical history and any contraindications listed in the SmPC.

Some conditions require particular care. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication. A history of pancreatitis, certain gastrointestinal conditions and active pregnancy or breastfeeding all require prescriber discussion before treatment proceeds. Tirzepatide is not licensed for anyone under 18. For women using oral contraceptives, the NHS tirzepatide page notes that an additional non-oral method of contraception is recommended during the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced.

If you are already on tirzepatide via another provider and want to understand the transfer process, the how to access Mounjaro through a private pharmacy page covers what evidence is typically needed. For a broader look at weight-loss treatment options beyond tirzepatide, the weight-loss treatment overview sets the landscape out without steering you toward any one path before a clinical review.